ArticleArthritis research & therapy2026
Proteomic landscape of IGF-I gene transfer in osteoarthritis-derived human bone marrow stromal cells undergoing chondrogenesis.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundOsteoarthritis (OA) is a progressive joint disease marked by the breakdown of cartilage and impaired repair capacity. Gene therapy applied to human bone marrow-derived adherent stromal cells (BM-MSCs) with recombinant adeno-associated virus (rAAV) vectors represents a promising strategy for cartilage regeneration. However, the molecular mechanisms underlying its effects remain largely unexplored. In this study, we investigated the proteomic changes induced by rAAV-mediated insulin-like growth factor I (IGF-I) gene transfer during the chondrogenic differentiation of BM-MSCs derived from OA patients.
methodsBM-MSCs from OA donors were transduced with recombinant rAAV vectors encoding either IGF-I or the lacZ gene (β-galactosidase) as a control and cultured in three-dimensional micromass systems under chondrogenic conditions for 21 days. Histological, immunohistochemical (IHC) and immunofluorescence (IF) analyses were performed to characterize the chondrogenic phenotype of the model and to provide orthogonal validation of selected proteomic findings. Mass spectrometry-based proteomic profiling identified protein detection patterns and quantitative changes associated with IGF-I overexpression. Pathway and protein-protein interaction (PPI) analyses were carried out to explore the functional implications of differentially expressed proteins.
resultsA total of 4,284 proteins were identified, of which 112 showed notable changes in detection patterns or abundance associated with IGF-I. Functional enrichment analyses showed involvement of pathways related to metabolism, endoplasmic reticulum (ER) homeostasis, apoptosis regulation, cell proliferation, glycosylation, and the endosomal sorting complex required for transport (ESCRT) machinery. Histological and IHC analyses provided supportive evidence of cartilage-related matrix deposition. Orthogonal validation by IHC and IF confirmed the IGF-I-mediated upregulation of β-catenin and exportin-1 (XPO1). Further analyses provided exploratory evidence of increased active β-catenin and predominantly extranuclear distribution of sirtuin-1, a known XPO1 substrate, in IGF-I-transduced micromasses.
conclusionThis study provides the first proteomic characterization of rAAV-mediated IGF-I gene therapy in OA-derived BM-MSCs undergoing chondrogenesis. The IGF-I gene transfer was associated with broad proteomic changes involving metabolic and protein processing pathways, and enhanced cartilage-specific matrix deposition, highlighting molecular mechanisms of potential relevance to cartilage repair in OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.